Convertissez Beldex BDX en VitaStem VITASTEM

Beldex building a decentralized confidential ecosystem in Web3 for secure digital interactions.. The concept of the project was developed in 2018, and launched in the same year. The Beldex project is committed to enhancing user data protection and their confidentiality online. BDX is an ecosystem coin that facilitates confidential transactions. Beldex's mission is to provide a confidential environment where data can be exchanged securely. The project is focused on individual safety and true data confidentiality with systematic research to ensure the confidentiality of individual transactions, and thus the safety of users and the security of their funds. BDX operates on the Beldex decentralized blockchain for performing secure transactions, while the ecosystem supports secure and confidential dApps, among them: BChat, BelNet, Beldex Browser, the Beldex protocol, and the Beldex bridge. Initially, Beldex was developed on a PoW architecture followed by a transition to the PoS consensus model in order to increase the scalability of the BDX token, lower fees and reduce transaction times.

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.